Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation

Bone Marrow Transplant. 2019 May;54(5):757-761. doi: 10.1038/s41409-018-0368-1. Epub 2018 Oct 24.

Authors

D Rivera^#¹, J M Bastida^#², L Lopez-Corral¹, F Sanchez-Guijo¹, M Cabrero¹, A Martin¹, E Perez¹, M Lopez-Parra¹, A Avendaño¹, A Veiga¹, M Baile¹, N Arratibel¹, J Carrillo¹, L Vazquez¹, M D Caballero¹, J R Gonzalez-Porras¹

Affiliations

¹ Department of Hematology, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain.
² Department of Hematology, Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain. jmbastida@saludcastillayleon.es.

^# Contributed equally.

PMID: 30356164
DOI: 10.1038/s41409-018-0368-1

No abstract available

Publication types

Clinical Trial
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Allografts
Benzoates / administration & dosage*
Benzoates / adverse effects
Female
Hematopoietic Stem Cell Transplantation*
Humans
Hydrazines / administration & dosage*
Hydrazines / adverse effects
Male
Middle Aged
Pyrazoles / administration & dosage*
Pyrazoles / adverse effects
Retrospective Studies
Thrombocytopenia / blood
Thrombocytopenia / drug therapy*
Thrombocytopenia / etiology

Substances

Benzoates
Hydrazines
Pyrazoles
eltrombopag